SEQ ID NO: 115 for CDRL1, SEQ ID NO: 116 for CDRL2 and SEQ ID NO: 117 for CDRL3.

24. A multispecific molecule according to any one of claims 1 to 20, wherein the binding domain specific for CD22 comprises 3 light chain CDRs having the sequence given in SEQ ID NO: 125 for CDRL1, SEQ ID NO: 126 for CDRL2 and SEQ ID NO: 127 for CDRL3.
25. A multispecific molecule according to any one of claims 1 to 20, wherein the binding domain specific for CD22 comprises 3 light chain CDRs having the sequence given in SEQ ID NO: 135 for CDRL1, SEQ ID NO: 136 for CDRL2 and SEQ ID NO: 137 for CDRL3
26. A multispecific molecule according to any one of claims 1 to 20, wherein the binding domain specific for CD22 comprises 3 light chain CDRs having the sequence given in SEQ ID NO: 145 for CDRL1, SEQ ID NO: 146 for CDRL2 and SEQ ID NO: 147 for CDRL3.
27. A multispecific molecule according to any one of claims 1 to 26 in which the binding domains are humanised.
28. A multispecific molecule according to any one of claims 11 to 27 in which one or more amino acids in one or more CDRs have been substituted with another amino acid.
29. A multispecific molecule according to claim 28 wherein one or more cysteine residues has been substituted with another amino acid.
30. A multispecific molecule according to claim 28 or claim 29 wherein one or more aspartic acid isomerisation sites and/or asparagine deamidation sites and/or glycosylation sites has been removed by substituting one or more amino acids in one or more CDRs.
31. A multispecific molecule according to any one of claims 1-30, which further comprises a binding domain specific to serum albumin, such as human serum albumin.
32. A composition comprising one or more multispecific proteins as defined in any one of claims 1 to 31.
33. A nucleotide sequence encoding a multispecific protein or component thereof as defined in any one of claims 1 to 31.
34. A vector comprising a nucleotide sequence defined in claim 33.
35. A multispecific protein according to any one of claims 1 to 31 or a composition according to claim 32, for use in therapy.
36. Use of a multispecific protein according to any one of claims 1 to 31 or a composition according to claim ~~30~~32, for the manufacture of a medicament for use in therapy, in particular for the treatment of a condition or disorder described herein.

~~37. A method of treating a patient, comprising the administration of a therapeutically effective amount of a multispecific protein according to any one of claims 1 to 31 or a composition according to claim 32.~~